Clinical Trial

the Efficacy and Safety of Rulonilimab in Combination With Lenvatinib in Hepatocellular Carcinoma

Study acronym: HCC
Unknown Phase 2/3
View on ClinicalTrials.gov →
Record status
This record was last updated March 10, 2023 (before its estimated August 1, 2025 completion). Its status may not reflect the trial's current state.
Summary
There are two studies included in this protocol. One is an open-label Phase Ⅱ study . The other is a multi-center, double-blind, randomized, phase III study .
Protocol Amendment History 1 change
critical Trial status changed: Recruiting → Unknown 2026-08-09
Trial Details
NCT Number NCT05408221
Lead Sponsor Shandong New Time Pharmaceutical Co., LTD
Conditions Hepatocellular Carcinoma
Enrollment 576 participants
Start Date 2022-11-11
Primary Completion 2025-08-01 (estimated)
Study Completion 2026-08-01 (estimated)
Updated on ClinicalTrials.gov 2023-03-10